問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間：2023-09-19

李柏昕
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

63Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李柏昕

List

80Cases

2024-09-01 - 2029-02-05

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting3Sites

2022-02-28 - 2026-12-10

Phase I/II

Active
An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

  • Condition/Disease

    Advanced Non-small Cell Lung Cancer、EGFR Mutation、HER2 Mutation

  • Test Drug

    BAY 2927088

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting2Sites

Terminated3Sites

2026-04-01 - 2029-11-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2026-03-01 - 2035-01-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2026-03-15 - 2032-10-25

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-10-01 - 2034-06-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2028-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-04-01 - 2027-08-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2025-09-01 - 2028-09-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-03-01 - 2026-10-30

Phase I

A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer

  • Condition/Disease

    HER2 Mutant Non-small Cell Lung Cancer

  • Test Drug

    ELVN-002ENHERTUKADCYLA

Participate Sites
3Sites

Recruiting3Sites

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB